Patents by Inventor Duane D. Miller
Duane D. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210161864Abstract: This invention is directed to selective androgen receptor degrader (SARD) compounds pharmaceutical compositions and uses thereof in treating early prostate cancer, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: August 31, 2020Publication date: June 3, 2021Applicant: University of Tennessee Research FoundationInventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Yali HE
-
Publication number: 20210024458Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: January 29, 2020Publication date: January 28, 2021Applicants: ONCTERNAL THERAPEUTICS, INC, University of Tennessee Research FoundationInventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Charles B. DUKE, Christopher C. COSS, Amanda JONES, James T. DALTON
-
Patent number: 10865184Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: September 5, 2018Date of Patent: December 15, 2020Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
-
Patent number: 10865196Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.Type: GrantFiled: January 16, 2018Date of Patent: December 15, 2020Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, ONCTERNAL THERAPEUTICS, INC.Inventors: Duane D. Miller, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn, Wei Li
-
Patent number: 10806719Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: May 16, 2018Date of Patent: October 20, 2020Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
-
Patent number: 10806720Abstract: This invention is directed to selective androgen receptor degrader (SARD) compounds pharmaceutical compositions and uses thereof in treating early prostate cancer, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: May 16, 2018Date of Patent: October 20, 2020Assignee: University of Tennessee Research FoundationInventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
-
Publication number: 20200317626Abstract: The present disclosure provides novel ATX inhibitors, and pharmaceutical compositions comprising said inhibitors, as well as methods of treatment comprising administration of said inhibitors.Type: ApplicationFiled: June 2, 2017Publication date: October 8, 2020Inventors: Duane D. MILLER, Gabor G. TIGYI, Souvik BANERJEE, Abby L. PARRILL-BAKER
-
Publication number: 20200299243Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: February 5, 2020Publication date: September 24, 2020Applicant: University of Tennessee Research FoundationInventors: Ramesh NARAYANAN, Duane D. MILLER, Thamarai PONNUSAMY, Dong-Jin HWANG, Yali HE
-
Publication number: 20200222365Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: ApplicationFiled: August 30, 2019Publication date: July 16, 2020Applicant: Oncternal Therapeutics, Inc.Inventors: Ramesh NARAYANAN, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He, Jayaprakash Pagadala, Christopher C. Coss, James T. Dalton, Charles B. Duke
-
Patent number: 10662148Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.Type: GrantFiled: February 2, 2018Date of Patent: May 26, 2020Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Ramesh Narayanan, Thamarai Ponnusamy, James T. Dalton, Duane D. Miller
-
Patent number: 10654809Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: March 16, 2018Date of Patent: May 19, 2020Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
-
Patent number: 10597354Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other 5 hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: October 5, 2018Date of Patent: March 24, 2020Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, ONCTERNAL THERAPEUTICS, INCInventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Charles B. Duke, Christopher C. Coss, Amanda Jones, James T. Dalton
-
Publication number: 20200039924Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including cyclic and heterocyclic anilide rings and their synthetic precursors, and mono-, di-, or multi-substituted N-heterocyclic rings, R-isomers, non-hydroxylated and/or non-chiral propanamides in treating androgen receptor dependent diseases and conditions such as hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamType: ApplicationFiled: May 29, 2019Publication date: February 6, 2020Applicant: University of Tennessee Research FoundationInventors: Ramesh NARAYANAN, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
-
Publication number: 20200024270Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.Type: ApplicationFiled: February 21, 2019Publication date: January 23, 2020Applicants: GTx, Inc., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Wei Li, Min Xiao, James Dalton, Sunjoo Ahn, Duane D. Miller, Jin Wang
-
Patent number: 10525037Abstract: The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.Type: GrantFiled: July 12, 2018Date of Patent: January 7, 2020Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Jin Wang, Jianjun Chen, Duane D. Miller, Wei Li
-
Publication number: 20190389841Abstract: The present invention encompasses methods of treating triple negative breast cancer and/or ovarian cancer using therapeutically effective amounts of compounds represented by the structure of formula I.Type: ApplicationFiled: May 15, 2019Publication date: December 26, 2019Applicants: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, VERU INCInventors: Wei LI, Duane D. MILLER, Shanshan DENG, Raya KRUTILINA, Tiffany N. SEAGROVES, Junming YUE, Guannan ZHAO, Wang QINGHUI, Mitchell S. STEINER
-
Publication number: 20190374512Abstract: The present invention encompasses methods of treating pancreatic cancer using therapeutically effective amounts of compounds represented by the structure of formula I.Type: ApplicationFiled: May 15, 2019Publication date: December 12, 2019Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: WEI LI, Duane D. MILLER, Subhash CHAUHAN, Vivek Kumar KASHYAP, Wang QINGHUI
-
Patent number: 10441570Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: May 16, 2018Date of Patent: October 15, 2019Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTX, INC.Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton
-
Patent number: 10314797Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.Type: GrantFiled: June 12, 2017Date of Patent: June 11, 2019Assignee: University of Tennessee Research FoundationInventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He
-
Patent number: 10301285Abstract: The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer.Type: GrantFiled: April 21, 2015Date of Patent: May 28, 2019Assignees: GTX, INC., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATIONInventors: Duane D. Miller, Jianjun Chen, James T. Dalton, Chien-Ming Li, Sunjoo Ahn, Wei Li